BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010;16:1905-1911. [PMID: 20310015 DOI: 10.1002/ibd.21260] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Iizuka M, Etou T, Sagara S. Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy. World J Gastroenterol 2022; 28(34): 4959-4972 [DOI: 10.3748/wjg.v28.i34.4959] [Reference Citation Analysis]
2 Bamias G, Zampeli E, Domènech E. Targeting neutrophils in inflammatory bowel disease: revisiting the role of adsorptive granulocyte and monocyte apheresis. Expert Rev Gastroenterol Hepatol 2022. [PMID: 35833363 DOI: 10.1080/17474124.2022.2100759] [Reference Citation Analysis]
3 Kishi M, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. J Gastroenterol 2022. [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y] [Reference Citation Analysis]
4 Fukuchi T, Kawashima K, Koga H, Utsunomiya R, Sugiyama K, Shimazu K, Eguchi T, Ishihara S. Induction of mucosal healing by intensive granulocyte/monocyte adsorptive apheresis (GMA) without use of corticosteroids in patients with ulcerative colitis: long-term remission maintenance after induction by GMA and efficacy of GMA re-treatment upon relapse. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ueno N, Sugiyama Y, Kobayashi Y, Murakami Y, Iwama T, Sasaki T, Kunogi T, Takahashi K, Tanaka K, Ando K, Kashima S, Inaba Y, Moriichi K, Tanabe H, Taruishi M, Saitoh Y, Okumura T, Fujiya M. Fecal calprotectin is a useful biomarker for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis in ulcerative colitis patients: a prospective observation study. BMC Gastroenterol 2021;21:316. [PMID: 34362299 DOI: 10.1186/s12876-021-01889-0] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Outtier A, Ferrante M. Chronic Antibiotic-Refractory Pouchitis: Management Challenges. Clin Exp Gastroenterol 2021;14:277-90. [PMID: 34163205 DOI: 10.2147/CEG.S219556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Iizuka M, Etou T, Shimodaira Y, Hatakeyama T, Sagara S. Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis. World J Gastroenterol 2021; 27(12): 1194-1212 [PMID: 33828394 DOI: 10.3748/wjg.v27.i12.1194] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Li N, Mao J, Tang H, Zhu L, Tan X, Bi J, Wu H, Chen X, Wang Y. Efficacy and safety of adsorptive granulomonocytapheresis in Chinese patients with ulcerative colitis: A retrospective analysis of 50 cases with focus on factors impacting clinical efficacy. J Clin Apher 2020;35:271-80. [PMID: 32378240 DOI: 10.1002/jca.21787] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Motoya S, Tanaka H, Shibuya T, Osada T, Yamamoto T, Hongo H, Mizuno C, Saito D, Aoyama N, Kobayashi T, Ito H, Tanida S, Nojima M, Kokuma S, Hosoi E. Safety and effectiveness of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease in special situations: a multicentre cohort study. BMC Gastroenterol. 2019;19:196. [PMID: 31752695 DOI: 10.1186/s12876-019-1110-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
10 Saniabadi AR, Tanaka T, Yamamoto T, Kruis W, Sacco R. Granulomonocytapheresis as a cell-dependent treatment option for patients with inflammatory bowel disease: Concepts and clinical features for better therapeutic outcomes. J Clin Apher. 2019;34:51-60. [PMID: 30407662 DOI: 10.1002/jca.21670] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
11 Wang JL, Gan YJ, Iqbal S, Jiang W, Yuan YY, Wang J. Delivery of tacrolimus with cationic lipid-assisted nanoparticles for ulcerative colitis therapy. Biomater Sci 2018;6:1916-22. [PMID: 29850666 DOI: 10.1039/c8bm00463c] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
12 Shimoyama T, Yamamoto T, Umegae S, Matsumoto K. Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC Gastroenterol 2018;18:120. [PMID: 30068300 DOI: 10.1186/s12876-018-0853-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
13 Yamamoto T, Iida T, Ikeya K, Kato M, Matsuura A, Tamura S, Takano R, Tani S, Osawa S, Sugimoto K, Shimoyama T, Hanai H. A multicenter retrospective study aiming to identify patients who respond well to adsorptive granulomonocytapheresis in moderately to severely active ulcerative colitis. Clin Transl Gastroenterol. 2018;9:170. [PMID: 29977035 DOI: 10.1038/s41424-018-0037-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
14 Laurent V, Naudé S, Vuitton L, Zallot C, Baumann C, Girard-Gavanier M, Peyrin-Biroulet L. Accuracy of Diffusion-weighted Magnetic Resonance Colonography in Assessing Mucosal Healing and the Treatment Response in Patients with Ulcerative Colitis. J Crohns Colitis 2017;11:716-23. [PMID: 27932450 DOI: 10.1093/ecco-jcc/jjw211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hagiwara SI, Okayasu I, Fujiwara M, Matsuura M, Ohnishi H, Ito S, Kishimoto H, Nambu R, Kagimoto S. Prostaglandin E-major Urinary Metabolite as a Biomarker for Pediatric Ulcerative Colitis Activity. J Pediatr Gastroenterol Nutr 2017;64:955-61. [PMID: 27906804 DOI: 10.1097/MPG.0000000000001477] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
16 Ono K, Nimura S, Hideshima Y, Nabeshima K, Nakashima M. Orally administered sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Exp Ther Med 2017;14:5485-90. [PMID: 29285080 DOI: 10.3892/etm.2017.5251] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
17 Iizuka M, Etou T, Kumagai M, Matsuoka A, Numata Y, Sagara S. Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis. Intern Med. 2017;56:2705-2710. [PMID: 28924114 DOI: 10.2169/internalmedicine.8428-16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
18 Tanaka T, Yamamoto T, Sawada K, Sacco R. Treatment options for children and adolescents with inflammatory bowel disease: is granulomonocytapheresis an effective alternative to drug therapy? Expert Rev Gastroenterol Hepatol. 2017;11:749-758. [PMID: 28612637 DOI: 10.1080/17474124.2017.1341309] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
19 Morabito V, Novelli S, Poli L, Ferretti G, Ruberto F, Pugliese F, Pretagostini R, Berloco PB, Rossi M. Adacolumn Granulocyte-Apheresis for Alcoholic Hepatitis: Preliminary Study. Transplant Proc. 2016;48:352-358. [PMID: 27109954 DOI: 10.1016/j.transproceed.2015.12.055] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
20 Yamamoto T, Tanaka T, Yokoyama T, Shimoyama T, Ikeuchi H, Uchino M, Watanabe T. Efficacy of granulocyte and monocyte apheresis for antibiotic-refractory pouchitis after proctocolectomy for ulcerative colitis: an open-label, prospective, multicentre study. Therap Adv Gastroenterol 2017;10:199-206. [PMID: 28203278 DOI: 10.1177/1756283X16679348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Shah SC, Colombel J, Sands BE, Narula N. Mucosal Healing Is Associated With Improved Long-term Outcomes of Patients With Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016;14:1245-1255.e8. [DOI: 10.1016/j.cgh.2016.01.015] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 26.5] [Reference Citation Analysis]
22 Ito A, Iizuka B, Omori T, Nakamura S, Tokushige K. Tacrolimus for Remission Induction and Maintenance Therapy in Patients with Ulcerative Colitis: A Retrospective Evaluation Study. Gastroenterol Res Pract 2016;2016:5956316. [PMID: 27413367 DOI: 10.1155/2016/5956316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Lourda M, Olsson-Åkefeldt S, Gavhed D, Axdorph Nygell U, Berlin G, Laurencikas E, von Bahr Greenwood T, Svensson M, Henter JI. Adsorptive depletion of blood monocytes reduces the levels of circulating interleukin-17A in Langerhans cell histiocytosis. Blood 2016;128:1302-5. [PMID: 27365427 DOI: 10.1182/blood-2016-03-708107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Ikeya K, Hanai H, Sugimoto K, Osawa S, Kawasaki S, Iida T, Maruyama Y, Watanabe F. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis. 2016;10:286-295. [PMID: 26581895 DOI: 10.1093/ecco-jcc/jjv210] [Cited by in Crossref: 64] [Cited by in F6Publishing: 75] [Article Influence: 9.1] [Reference Citation Analysis]
25 Schechter A, Griffiths C, Gana JC, Shaoul R, Shamir R, Shteyer E, Bdolah-Abram T, Ledder O, Turner D. Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric ulcerative colitis. Gut 2015;64:580-8. [PMID: 24848266 DOI: 10.1136/gutjnl-2014-306999] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 6.1] [Reference Citation Analysis]
26 Yokoyama Y, Watanabe K, Ito H, Nishishita M, Sawada K, Okuyama Y, Okazaki K, Fujii H, Nakase H, Masuda T, Fukunaga K, Andoh A, Nakamura S. Factors associated with treatment outcome, and long-term prognosis of patients with ulcerative colitis undergoing selective depletion of myeloid lineage leucocytes: a prospective multicenter study. Cytotherapy. 2015;17:680-688. [PMID: 25804800 DOI: 10.1016/j.jcyt.2015.02.007] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
27 Ruemmele FM, Hyams JS, Otley A, Griffiths A, Kolho KL, Dias JA, Levine A, Escher JC, Taminiau J, Veres G, Colombel JF, Vermeire S, Wilson DC, Turner D. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut 2015;64:438-46. [PMID: 24821616 DOI: 10.1136/gutjnl-2014-307008] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
28 Ikeya K, Sugimoto K, Kawasaki S, Iida T, Maruyama Y, Watanabe F, Hanai H. Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. Dig Liver Dis. 2015;47:365-371. [PMID: 25682993 DOI: 10.1016/j.dld.2015.01.149] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
29 Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
30 Pagnini C, Menasci F, Festa S, Rizzatti G, Fave GD. “Mucosal healing” in ulcerative colitis: Between clinical evidence and market suggestion. World J Gastrointest Pathophysiol 2014; 5(2): 54-62 [PMID: 24891976 DOI: 10.4291/wjgp.v5.i2.54] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
31 Ono K, Nimura S, Nishinakagawa T, Hideshima Y, Enjyoji M, Nabeshima K, Nakashima M. Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Exp Ther Med 2014;7:573-8. [PMID: 24520247 DOI: 10.3892/etm.2013.1456] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
32 Yoshino T, Nakase H, Minami N, Yamada S, Matsuura M, Yazumi S, Chiba T. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis. 2014;46:219-226. [PMID: 24268950 DOI: 10.1016/j.dld.2013.10.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
33 Bamba T, Yamamoto T, Umegae S, Matsumoto K. Effects of preoperative leukocytapheresis on inflammatory cytokines following surgery for ulcerative colitis: a prospective randomized study. J Clin Apher. 2014;29:107-112. [PMID: 24000140 DOI: 10.1002/jca.21299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
34 Turner D, Griffiths AM, Veerman G, Johanns J, Damaraju L, Blank M, Hyams J. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab. Clin Gastroenterol Hepatol. 2013;11:1460-1465. [PMID: 23672831 DOI: 10.1016/j.cgh.2013.04.049] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
35 Yokoyama Y, Kawai M, Fukunaga K, Kamikozuru K, Nagase K, Nogami K, Kono T, Ohda Y, Iimuro M, Hida N, Nakamura S, Miwa H, Matsumoto T. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27. [PMID: 23399416 DOI: 10.1186/1471-230x-13-27] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
36 Okuyama Y, Andoh A, Nishishita M, Fukunaga K, Kamikozuru K, Yokoyama Y, Ueno Y, Tanaka S, Kuge H, Yoshikawa S, Sugahara A, Anami E, Munetomo Y, Watanabe C, Fujiyama Y, Matsumoto T. Multicenter prospective study for clinical and endoscopic efficacies of leukocytapheresis therapy in patients with ulcerative colitis. Scandinavian Journal of Gastroenterology 2012;48:412-8. [DOI: 10.3109/00365521.2012.763175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
37 Vecchi M, Vernia P, Riegler G, D’Incà R, Annese V, Bagnoli S. Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be? Clin Exp Gastroenterol. 2013;6:1-7. [PMID: 23323022 DOI: 10.2147/ceg.s33275] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
38 Hiraoka S, Kato J, Suzuki H, Yamamoto K. Readministration of calcineurin inhibitors for ulcerative colitis. Ann Pharmacother 2012;46:1315-21. [PMID: 23032660 DOI: 10.1345/aph.1R210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
39 Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, Riestra S, de Francisco R, Papo M, Borruel N. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012;24:762-769. [PMID: 22517240 DOI: 10.1097/meg.0b013e32835414b2] [Cited by in Crossref: 61] [Cited by in F6Publishing: 64] [Article Influence: 6.1] [Reference Citation Analysis]
40 Yamamoto T. The role of granulocyte and monocyte apheresis in inflammatory bowel disease. J Crohns Colitis 2013;7:e114. [PMID: 22868064 DOI: 10.1016/j.crohns.2012.07.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 C Leitner G, Worel N, Vogelsang H. Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease. Transfus Med Hemother 2012;39:246-52. [PMID: 22969694 DOI: 10.1159/000341801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
42 Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine. Clin Pharmacol. 2012;4:41-50. [PMID: 22888278 DOI: 10.2147/CPAA.S26556] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
43 Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohns Colitis 2012;6:750-5. [PMID: 22398094 DOI: 10.1016/j.crohns.2011.12.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
44 Cabriada JL. Aféresis en enfermedad inflamatoria intestinal. ¿Una opción válida? Gastroenterología y Hepatología 2012;35:22-31. [DOI: 10.1016/j.gastrohep.2011.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Meucci G, Fasoli R, Saibeni S, Valpiani D, Gullotta R, Colombo E, D’Incà R, Terpin M, Lombardi G. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2012;18:1006-1010. [PMID: 21830282 DOI: 10.1002/ibd.21838] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 7.7] [Reference Citation Analysis]
46 Peyrin-Biroulet L, Ferrante M, Magro F, Campbell S, Franchimont D, Fidder H, Strid H, Ardizzone S, Veereman-Wauters G, Chevaux JB. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5:477-483. [PMID: 21939925 DOI: 10.1016/j.crohns.2011.06.009] [Cited by in Crossref: 204] [Cited by in F6Publishing: 202] [Article Influence: 18.5] [Reference Citation Analysis]
47 López-Palacios N, Mendoza JL, Taxonera C, Lana R, López-Jamar JM, Díaz-Rubio M. Mucosal healing for predicting clinical outcome in patients with ulcerative colitis using thiopurines in monotherapy. Eur J Intern Med 2011;22:621-5. [PMID: 22075292 DOI: 10.1016/j.ejim.2011.06.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
48 Yamamoto T, Umegae S, Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol 2011;46:1003-9. [PMID: 21681409 DOI: 10.1007/s00535-011-0428-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
49 Iizuka M, Sagara S, Etou T. Efficacy of long-interval cytapheresis on steroid-dependent refractory ulcerative colitis. Inflamm Bowel Dis 2011;17:E119-20. [PMID: 21674727 DOI: 10.1002/ibd.21786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 5.1] [Reference Citation Analysis]
51 Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]